文献速递慢性静脉疾病

氰基丙烯酸酯栓塞治疗反流性大隐静脉:欧洲多中心前瞻性队列3年随访结果

Three-year follow-up results of the prospective European Multicenter Cohort Study on Cyanoacrylate Embolization for treatment of refluxing great saphenous veins.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-06-26

这项欧洲七中心前瞻性非随机队列研究纳入70例反流性大隐静脉患者,采用氰基丙烯酸酯栓塞治疗,不使用肿胀麻醉或术后弹力袜。3年随访时64例(91%)可评估,Kaplan-Meier闭合率在6、12、24、36个月分别为91.4%、90.0%、88.5%、88.5%,静脉临床严重程度评分从基线4.3降至36个月0.9(P < .001)。

要点

  • 氰基丙烯酸酯栓塞治疗反流性大隐静脉3年闭合率维持在88.5%。
  • 静脉临床严重程度评分从基线4.3显著降至36个月0.9(P < .001)。
  • 治疗未使用肿胀麻醉或术后弹力袜,3年解剖与临床有效性持续。

核心结论

  • eSCOPE研究3年随访显示氰基丙烯酸酯栓塞治疗反流性大隐静脉具有持续的解剖和临床有效性。

研究设计与样本

  • 前瞻性、多中心、非随机队列研究,在欧洲4国7个中心纳入70例接受单支反流性大隐静脉氰基丙烯酸酯栓塞治疗的患者。
  • 主要有效性终点为6个月大隐静脉免于再通(闭合率),安全性评估术后及6个月随访期间不良事件。

主要发现

  • 70例治疗患者中64例(91%)完成3年随访。
  • Kaplan-Meier法6、12、24、36个月闭合率分别为91.4%、90.0%、88.5%、88.5%。
  • 静脉临床严重程度评分均值从基线4.3降至36个月随访0.9(P < .001)。

关键数值与推荐

  • 6个月闭合率91.4%,12个月90.0%,24个月88.5%,36个月88.5%。
  • 静脉临床严重程度评分从基线4.3降至36个月0.9(P < .001)。

临床怎么用

  • 氰基丙烯酸酯栓塞可作为反流性大隐静脉的治疗选择,3年随访显示闭合率维持且临床症状改善。
  • 治疗可不使用肿胀麻醉或术后弹力袜,但需结合患者具体情况评估。

局限性

  • 研究为非随机队列设计,样本量70例,3年随访时64例可评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cyanoacrylate closure of refluxing saphenous veins has demonstrated excellent safety and effectiveness results in feasibility and pivotal studies. This article provides the 36-month follow-up results of a prospective, multicenter, nonrandomized cohort study. METHODS: A total of 70 patients were enrolled in a prospective, multicenter study conducted at seven centers in four European countries and underwent treatment of a solitary refluxing great saphenous vein with endovenous cyanoacrylate embolization without the use of tumescent anesthesia or postprocedure compression stockings. The primary effectiveness end point was freedom from recanalization (closure rate) of the great saphenous vein at 6 months. Safety was assessed by occurrence of adverse events after the procedure and during the 6-month follow-up period. Quality of life and clinical improvement parameters were measured before and after the procedure and through a 12-month follow-up period. Anatomic success and clinical improvement were assessed through 36 months after the procedure. RESULTS: Of 70 treated patients, 64 (91%) were available for the 3-year follow-up. The closure rates by Kaplan-Meier life table methods at 6-, 12-, 24-, and 36-month time points were 91.4%, 90.0%, 88.5%, and 88.5%, respectively. Through 36 months, the improvement in change of the mean venous clinical severity score over time was statistically significant by dropping from 4.3 at baseline to 0.9 at the 36-month follow-up (P < .001). CONCLUSIONS: The 3-year follow-up results of the prospective, multicenter eSCOPE study demonstrated the continued anatomic and clinical effectiveness of cyanoacrylate embolization over an extended follow-up period.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European Multicenter Cohort Study on Cyanoacrylate Embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32599306. doi:10.1016/j.jvsv.2020.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。